Scientific Advisory Boards Behind Direct-to-Consumer Longevity Testing Companies

Direct-to-consumer longevity testing grew fast, and that growth turned the scientific advisory board into a standard feature of company branding. A company needed some quick, visible proof that its test was built on real science, and a board of recognizable researchers became the fastest way to supply that proof. So the SAB spread across the sector: companies with genuine peer-reviewed research programs built them, and companies that needed a credibility boost for a landing page built them too. From the outside, both look the same. A list of names, a row of headshots, a string of PhDs after each one. But what if the board itself tells you almost nothing on its own? That's the situation most people shopping for a biological age test are actually in: unable to tell, at a glance, which board reflects real oversight and which one is decoration. The credential has become so common that it has stopped functioning as a credential, so reading it requires a framework.

What a scientific advisory board is supposed to do

A real scientific advisory board shapes how a company does its research. It weighs in on how studies get designed, which biomarkers get selected, and how findings get translated into something a customer can read and understand. That's a different relationship than an endorsement deal, where a well-known name simply agrees to be associated with a product.

A functioning SAB does a specific set of jobs. It reviews whether the company's assays and algorithms hold up scientifically. It advises on study design and on where and how to publish results. It flags claims that are getting ahead of the evidence behind them. And it guides how raw findings turn into the plain-language interpretations a customer actually sees on their results page.

Insilico Medicine's Longevity Board, announced in April 2026, operates in drug discovery rather than consumer diagnostics, but it shows what this looks like when it's spelled out clearly. The board is chartered to oversee work on life models, biomarkers of aging, the identification of dual-purpose targets implicated in both aging and disease, and clinical development validating how therapeutics affect the hallmarks of aging using biomarkers and foundation models. That's a defined scientific mandate, not a vague advisory relationship. The same standard carries over to DTC diagnostics: a board with a stated remit, covering which algorithms it validates and which claims require published evidence, is structurally different from a board with no described function. When a company talks about its SAB in vague terms, like "guides our scientific direction," that language is doing less work than something specific, like "reviews all algorithm updates before publication" or "has co-authored peer-reviewed studies using our platform data."

The spectrum from genuine oversight to credentialed window-dressing

Real SABs sit somewhere on a spectrum. At one end, a board has materially shaped a company's published science. At the other, a board's connection to what the company actually sells is hard to pin down.

Elysium Health sits closer to the oversight end, anchored in a documented research history. The company was co-founded by Leonard Guarente, Ph.D., a scientist known for seminal contributions to NAD+ and sirtuin biology. Its biological age test, Index, was developed in collaboration with epigenetic aging researcher Morgan Levine, Ph.D., at Yale. That's an institutional partnership with a specific name and a specific institution attached to it, which is a different kind of claim than a general nod to "working with top scientists."

Insilico Medicine offers a different version of the same oversight principle: longevity demonstrated through tenure. Michael Levitt, PhD, the 2013 Nobel Laureate in Chemistry, has served on the company's scientific advisory board since 2014. That relationship predates the current wave of longevity-market enthusiasm by roughly a decade, which carries more weight than a Nobel laureate's name appearing on a board assembled last year.

On the other end of the spectrum, watch for a board where the members' published research doesn't overlap with the specific type of test the company sells, where no co-authored studies exist connecting the advisors to the company's methods, and where the company's own website never explains what the board actually reviews. None of that points to any one company. It describes a recognizable shape: credentials assembled for appearance, disconnected from the function they're meant to signal. A board stitched together right after a funding round, with no publication history linking its members to the company's actual methodology, carries less weight than one built on a relationship that existed before the product did.

What advisor credentials do and do not tell you

An advisor's credentials matter to a company's scientific claims only when those credentials line up with the specific methodology the company uses. Prestige in a nearby field doesn't transfer automatically. A brilliant chemist is not automatically a brilliant judge of a consumer methylation panel, and the only way to know is to check.

A few questions do most of the work here. If the company's test is epigenetic, does the advisor's published research involve DNA methylation clocks? Does it involve protein biology, if the test is proteomic? Does it involve glycan testing, if the test measures IgG glycosylation? Has the advisor published using the specific kind of data the company generates, or only in some neighboring corner of aging biology? Is the advisor a named co-author on the studies the company actually cites, or just a general supporter whose name shows up on a page?

Call this the Nobel problem. A major prize in chemistry or physics doesn't automatically confer expertise in clinical epigenomics or in validating a consumer diagnostic. Michael Levitt's Nobel Prize recognized the development of multiscale models for complex chemical systems, work with obvious value for AI-driven drug discovery. Whether that same expertise bears on interpreting a saliva-based methylation panel sold to a consumer is a separate question, worth asking about any advisor regardless of how decorated they are.

Institutional affiliations deserve the same scrutiny. A line like "developed in partnership with Harvard and Yale" describes a collaboration, but it doesn't say whether that collaboration produced a peer-reviewed publication, a licensed algorithm, or something closer to an informal conversation. The strongest signal available is a specific, named publication in a peer-reviewed journal, where the advisor appears as an author and the company's own data or platform is the actual subject of the paper. Anyone can check that in a PubMed search. Proteomic aging clocks, which measure protein abundance in blood rather than DNA methylation, are a good test case: researchers like Tony Wyss-Coray at Stanford have published peer-reviewed work in this space, and a company claiming its proteomic test is validated should be able to point directly to that literature, not just to Wyss-Coray's institutional title.

Reading what a company publishes about its SAB

The way a company writes about its SAB on its own website is itself a useful diagnostic. Specific language, traceable claims, and linked publications point toward a functioning board. Vague bios and unlinked claims point the other way.

Named advisors whose publication records are searchable and relevant to the company's specific methodology are a strong signal (PubMed is free and open to anyone who wants to look). A clear description of what the board actually does, how often it meets, and what authority it has over the claims a company makes publicly. Co-authored or company-funded studies, published in peer-reviewed journals, with the study design and funding source disclosed. Transparency about algorithm updates, including whether the company explains when and how its biological age clock changes and how that change gets validated.

Advisor bios that describe general expertise, "expert in aging biology," without linking to any research tied to the actual product, are a weaker signal. Claims of institutional partnership with no linked publication and no named collaborator attached. A board that appears or expands right around a funding announcement or product launch, with no publication history connecting those names to the company beforehand. A page that lists names and titles and stops there, with no explanation of what the board is actually for.

One practical check takes a couple of minutes: search an advisor's name alongside the company's product name, or the specific type of assay, on Google Scholar or PubMed. If nothing turns up, that advisor's connection to the product hasn't been demonstrated anywhere public. A second check is just as useful: notice whether the company separates peer-reviewed evidence for the underlying clock or assay, which may be well established, from peer-reviewed evidence that its own specific implementation of that clock is valid. Those are two different claims, and conflating them is common. A related conflation occurs around lab certification. CLIA certification confirms that a lab handles and processes samples according to regulatory standards. It says nothing about whether the scientific interpretation of the results is sound. Company marketing frequently blurs these two forms of credibility together, and reading them separately takes only a moment. None of these checks require special training, and any company with real scientific governance behind it will pass them without friction.

The honest limit of SAB scrutiny: what no advisory board can tell you

Even a well-governed SAB cannot close the field's biggest open question. No company in the DTC longevity testing space, however good its science, has established that a lower biological age score translates into better health outcomes. That's a limitation of the category itself, not a failure specific to any one product, and it's acknowledged even by analysts who cover the sector.

A biological age score, whether it describes the whole body or a single organ, is a model's output. It is not a clinical diagnosis. An SAB can confirm that the model behind that score is scientifically sound, built on real data and reasonable assumptions. It cannot yet confirm that acting on that score, say, changing a habit because a number moved, actually changes the trajectory of a person's aging. The underlying science connecting epigenetic age acceleration to things like all-cause mortality, cardiovascular risk, and cognitive decline is itself peer-reviewed and has been replicated across studies. The open question sits one step further down the line: whether intervening on a test score changes outcomes the way intervening on, say, blood pressure does.

The most credible companies in this space are upfront about that distinction. They describe their products as preventive-health and research tools, not as clinical diagnostics that dictate treatment. An SAB that lets its company overstate what a score means, or that encourages that kind of overclaiming, is failing at one of its core jobs, no matter how impressive the names on the roster are. One might argue that this caveat undercuts the whole case for paying attention to SABs in the first place, but it doesn't. It sharpens what a good board is actually for: not promising a cure, but holding a company to the line between what the science supports and what it doesn't yet. As the field matures, the companies that last are likely to be the ones whose boards are enforcing that line now, while it's still tempting to blur it.

What a well-credentialed SAB signals

A genuinely functional SAB tells you something beyond the quality of the science. It tells you that a company has built itself to answer to evidence rather than to sales targets: are this company's incentives aligned with the people paying for its tests, or with its next funding round?

A company whose SAB has a stated mandate, whose advisors' expertise actually matches its methodology, and which publishes its validation work, is making an implicit commitment. It's agreeing to be held to a standard, one that researchers can check, regulators can scrutinize, and customers can verify for themselves with a PubMed search. That kind of accountability matters more in a market where pricing is often opaque, where the same underlying algorithm can be licensed out and repackaged under different brand names, and where functionally identical tests can carry wildly different price tags depending on how they're bundled.

The same logic extends past the SAB into how a company runs everything else. Transparent pricing, published methods, and honest communication about what a result does and doesn't mean are all expressions of the same underlying incentive alignment. A company that's honest about its science tends to be honest about what it charges and why.

For anyone weighing a DTC longevity testing product, the SAB is one input, not the whole decision. A short checklist does most of the work: Does the board have a stated function? Do the advisors' credentials actually match the company's methodology? Is there a real, searchable, peer-reviewed publication record behind the claims? Does the company communicate honestly about what its results can and can't tell someone? And does the pricing make clear what's actually being paid for? Running through those five questions takes less time than reading the company's own marketing copy, and it tells a reader far more.